Company Filing History:
Years Active: 2024
Title: The Innovative Contributions of Jeffrey M. Schkeryantz
Introduction
Jeffrey M. Schkeryantz is a notable inventor based in Summit, NJ (US). He has made significant contributions to the field of neurodegenerative disease treatment through his innovative research and development efforts. His work focuses on the modulation of specific compounds that can potentially improve the lives of those affected by neurological disorders.
Latest Patents
Jeffrey M. Schkeryantz holds 1 patent for his invention titled "Carboxylic acid containing azetidinyl compounds for the treatment of neurodegenerative diseases." This patent provides compounds and compositions aimed at modulating S1P5, which are essential for the treatment of various neurological diseases.
Career Highlights
Currently, Jeffrey is associated with Celgene Corporation, a leading biopharmaceutical company known for its innovative approaches to treating serious diseases. His role at Celgene has allowed him to collaborate with other talented professionals in the field, further enhancing his contributions to medical science.
Collaborations
Throughout his career, Jeffrey has worked alongside esteemed colleagues such as Karin Irmgard Worm and Rulin Ma. These collaborations have fostered a productive environment for innovation and research, leading to advancements in the treatment of neurodegenerative diseases.
Conclusion
Jeffrey M. Schkeryantz's work exemplifies the impact of innovation in the medical field, particularly in addressing the challenges posed by neurodegenerative diseases. His contributions continue to inspire future research and development in this critical area of healthcare.